MX2017015456A - Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos. - Google Patents

Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos.

Info

Publication number
MX2017015456A
MX2017015456A MX2017015456A MX2017015456A MX2017015456A MX 2017015456 A MX2017015456 A MX 2017015456A MX 2017015456 A MX2017015456 A MX 2017015456A MX 2017015456 A MX2017015456 A MX 2017015456A MX 2017015456 A MX2017015456 A MX 2017015456A
Authority
MX
Mexico
Prior art keywords
methods
initiation
inhibition
translation
diseases
Prior art date
Application number
MX2017015456A
Other languages
English (en)
Inventor
Alan B Cooper
Stephane Ciblat
Arshad Siddiqui M
Dery Martin
Constantineau-Forget Lea
Grand-Maitre Chantal
Guo Xiangyu
Srivastava Sanjay
W Shipps Gerald
Bruneau-Latour Nicolas
Linh Ly Vu
Original Assignee
Bantam Pharmaceutical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bantam Pharmaceutical Llc filed Critical Bantam Pharmaceutical Llc
Publication of MX2017015456A publication Critical patent/MX2017015456A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de pirazol, así como composiciones farmacéuticas y métodos de uso de los mismos. Una modalidad es un compuesto que tiene la estructura (I) y sales farmacéuticamente aceptables y N-óxidos de los mismos, en donde X1, X2, Z1, Z2, el sistema de anillo indicado por "a", R1, A1A, L1B, L1A, L2, Q, L3, R3, A4A, L4B, A4B, L4A, R4, L5 y R5 son como se describen aquí. En ciertas modalidades, los compuestos descritos aquí rompen la interacción elF4E/eiF4G, y pueden usarse para tratar un trastorno hiperproliferativo, una enfermedad o trastorno neurológico, o autismo.
MX2017015456A 2015-06-01 2016-06-01 Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos. MX2017015456A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562169376P 2015-06-01 2015-06-01
PCT/US2016/035288 WO2016196644A1 (en) 2015-06-01 2016-06-01 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto

Publications (1)

Publication Number Publication Date
MX2017015456A true MX2017015456A (es) 2018-11-29

Family

ID=56118071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015456A MX2017015456A (es) 2015-06-01 2016-06-01 Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos.

Country Status (9)

Country Link
US (2) US10537558B2 (es)
EP (1) EP3303332A1 (es)
JP (1) JP6707630B2 (es)
CN (1) CN108349962A (es)
BR (1) BR112017025851A2 (es)
CA (1) CA3025492A1 (es)
IL (1) IL255898A (es)
MX (1) MX2017015456A (es)
WO (1) WO2016196644A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017015456A (es) 2015-06-01 2018-11-29 Bantam Pharmaceutical Llc Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos.
US12150934B2 (en) 2016-11-30 2024-11-26 Bantam Pharmaceutical, Llc Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
CA3081983A1 (en) * 2016-11-30 2018-06-07 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
JP7301042B2 (ja) 2018-03-30 2023-06-30 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除組成物
BR112020024794A2 (pt) * 2018-06-07 2021-03-02 Bantam Pharmaceutical, Llc métodos de tratamento de câncer com compostos de pirrol e pirazol substituídos e diagnóstico de câncer suscetível a tratamento com compostos de pirrol e pirazol substituídos
WO2020051424A1 (en) 2018-09-07 2020-03-12 Pic Therapeutics Eif4e inhibitors and uses thereof
CN110950848B (zh) * 2018-09-27 2024-03-26 徐诺药业 新型氨基吡唑类衍生物的合成与应用
CN114867724B (zh) * 2019-05-31 2025-11-07 班塔姆制药有限责任公司 用于制备噻唑基吡唑甲酸及其中间体的方法
CN114502551B (zh) 2019-11-01 2023-08-22 优迈特株式会社 含氟嘧啶化合物及其制备方法
TW202146393A (zh) 2020-03-03 2021-12-16 美商皮克醫療公司 Eif4e抑制劑及其用途
CA3229560A1 (en) 2021-08-25 2023-03-02 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
IT1301968B1 (it) * 1998-07-30 2000-07-20 Zambon Spa Derivati di eritromicina ad attivita' antibiotica
EP1104759B1 (en) * 1999-12-03 2003-10-22 Pfizer Products Inc. Heteroaryl phenyl pyrazole compounds as anti-inflammatory/analgesic agents
AU2003226252A1 (en) * 2002-04-04 2003-10-20 Cv Therapeutics, Inc. Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
CN100387594C (zh) 2003-04-03 2008-05-14 麦克公司 二芳基取代的吡唑类代谢型谷氨酸受体-5调节剂
CA2522476A1 (en) 2003-04-18 2004-11-04 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2007138110A2 (en) * 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
CN101835377B (zh) * 2007-08-27 2014-12-10 巴斯夫欧洲公司 用于防治无脊椎动物害虫的吡唑化合物
CA2720343A1 (en) * 2008-04-04 2009-10-08 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
KR101608259B1 (ko) 2008-04-28 2016-04-01 교린 세이야꾸 가부시키 가이샤 시클로펜틸아크릴산아미드 유도체
WO2012080729A2 (en) * 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
EP2909203A4 (en) 2012-10-22 2016-04-06 Egenix Inc COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES OR DISEASES RELATED TO EIF4E MALFUNCTION
WO2015144290A1 (en) 2014-03-27 2015-10-01 Merck Patent Gmbh Pyridyl piperidines
CN108040481B (zh) 2015-04-24 2020-10-30 先正达参股股份有限公司 具有硫取代的五元环杂环的杀有害生物活性多环衍生物
MX2017015456A (es) 2015-06-01 2018-11-29 Bantam Pharmaceutical Llc Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos.

Also Published As

Publication number Publication date
JP6707630B2 (ja) 2020-06-10
US11602526B2 (en) 2023-03-14
US10537558B2 (en) 2020-01-21
CN108349962A (zh) 2018-07-31
EP3303332A1 (en) 2018-04-11
US20180311218A1 (en) 2018-11-01
US20200261424A1 (en) 2020-08-20
JP2018521119A (ja) 2018-08-02
IL255898A (en) 2018-01-31
WO2016196644A1 (en) 2016-12-08
BR112017025851A2 (pt) 2018-10-16
CA3025492A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
MX2017015456A (es) Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos.
PH12019502436A1 (en) 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors
ZA202006137B (en) Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
PH12016502318A1 (en) Cyclic di-nucleotides as modulators of sting
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
PH12014500919A1 (en) (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
MY190408A (en) Compositions and methods for treating cns disorders
MX2016013529A (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
WO2018111315A8 (en) PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES
PH12021553248A1 (en) Heterocyclic monoacylglycerol lipase (magl) inhibitors
PH12013501393A1 (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
MY202884A (en) Compounds useful in hiv therapy
ZA201607489B (en) Combination comprising a glucocorticoid and edo-s101
ZA202000028B (en) Use of vibegron to treat overactive bladder
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
MX2019007213A (es) Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina.
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators
MY193963A (en) Composition for treating joint diseases and kit containing same
EP4620940A3 (en) Synthesis of (+)-cannabinoids and their therapeutic effects
JOP20180057A1 (ar) مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
WO2016119031A8 (pt) Composto, processo de síntese do composto, uso, composição farmacêutica, método de tratamento de inflamações ou de doença neurodegenerativa, forma de dosagem oral e método de inibição de enzima acetilcolinesterase